Inhalation Sciences: Corfind interviews CEO Manoush Masarrat on an eventful 2020

(Stockholm Jan 8, 2020) Inhalation Sciences (ISAB) today publishes a video interview with CEO Manoush Masarrat on ISAB’s progress in 2019 and the year ahead.

In the film, Manoush Masarrat describes ISAB’s broad and growing customer base, its unique in vitro simulation tool DissolvIt, which the company expects to launch in Q1 2020, and its current clinical trials for PreciseInhale.

The film is available HERE.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we inhale them.

The information above was provided through the agency of the contact person above, for publication on January 8, 2020.

Tags: